AndrewScottPaulsonMD

Oncology • Dallas, TX

Gastrointestinal Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Paulson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Paulson's full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1000

Fax+1 214-370-1085

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2011 - 2013
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
University of Texas Southwestern Medical SchoolClass of 2008

Certifications & Licensure

CA State Medical License 2011 - Present
TX State Medical License 2014 - 2026
MA State Medical License 2010 - 2011
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Clinical Trials

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Start of enrollment: 2018 Apr 18
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

1594 citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara
The Lancet. Oncology. 2018-07-01
824 citations
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi
The Lancet. Oncology. 2020-05-01
27 citations
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase ...
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, Tim Larson, Allen L Cohn
Eclinicalmedicine. 2023-04-01

Lectures

Impact of gastric cancer treatment pathways on patient outcomes in a community oncology practice setting.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020

Press Mentions

7 Major Changes to Public Service Loan ForgivenessJuly 6th, 2023
Want to Shorten Your Student Loan Repayment? The PSLF Buyback Can HelpMarch 26th, 2024